

Supplementary table S1	Bioclinical characteristics of subject with severe obesity, stratified by metabolic health groups: Values are n(%) for categorical variables and median (1st quartile, 3rd quartile) for continuous variables. P-values were obtained via Chi ² tests and Kruskal-Wallis tests, respectively. Abbreviations: SOB-MH: severely obese, metabolically healthy; SOB-MUH: severely obese, metabolically unhealthy; SOB-T2D: severely obese, type 2 diabetic.
Supplementary table S2	Bioclinical characteristics of non-obese and moderately obese participants, stratified by study groups: Values are n(%) for categorical variables and median (1st quartile, 3rd quartile) for continuous variables. P-values were obtained via Chi ² tests and Kruskal-Wallis tests, respectively - for the comparison of differences between groups NOB-MH, NOB-MUH, NOB-T2D and between groups MOB-MH, MOB-MUH, MOB-T2D. Abbreviations: NOB: non-obese; MOB: moderately obese; MH: metabolically healthy; MUH: metabolically unhealthy; T2D: type-2 diabetic.
Supplementary table S3	Drug treatment characteristics of participants, stratified by obesity groups: Values are n (%). "Insulin" includes both basal and bolus insulin. Abbreviations: NON-SOB: not severely obese; SOB: severely obese; MH: metabolically healthy; MUH: metabolically unhealthy; T2D: type 2 diabetic
Supplementary table S4	Types of antidiabetic medications prescribed within the study groups including diabetic participants: This table only shows isolated drug treatments or treatment combination with a frequency of n>=10. Values are n(%), and p-values for differences across obesity groups were obtained from Chi ² tests, except for "Sulfonylurea only", "Metformin + Insulin", and "Metformin + GLP-1 receptor antagonists + Sulfonylurea", where Fisher's exact tests were used

Supplementary Table 1

	SOB-MH	SOB-MUH	SOB-T2D	p
n	161	219	228	
Age, y	43.00 [33.00, 52.00]	48.00 [37.00, 56.50]	57.00 [47.00, 63.25]	<0.001
Gender = Male	28 (17.4)	52 (23.7)	87 (38.2)	<0.001
Country				0.033
Danemark	2 (1.2)	13 (5.9)	11 (4.8)	
France	90 (55.9)	92 (42.0)	106 (46.5)	
Germany	69 (42.9)	114 (52.1)	111 (48.7)	
Body mass index, kg/m²	41.59 [38.42, 45.80]	42.77 [38.99, 48.72]	40.87 [37.14, 46.63]	0.004
% Body fat	47.61 [45.17, 50.56]	48.42 [44.88, 51.16]	46.42 [40.93, 50.30]	0.001
Waist circumference, cm	119.10 [111.00, 128.20]	125.30 [115.75, 137.65]	126.00 [116.15, 140.00]	<0.001
Systolic blood pressure, mm hg	121.50 [115.00, 127.50]	131.25 [122.00, 139.50]	132.50 [120.50, 143.00]	<0.001
Diastolic blood pressure, mm hg	73.00 [66.50, 80.00]	76.50 [71.00, 86.50]	76.00 [67.50, 84.50]	0.001
Fasting blood glucose, mmol/l	5.00 [4.70, 5.24]	5.60 [5.10, 5.91]	7.53 [6.21, 9.12]	<0.001
HbA1c, %	5.55 [5.37, 5.80]	5.72 [5.45, 6.00]	6.80 [6.24, 7.62]	<0.001
HDL cholesterol, mmol/l	1.37 [1.23, 1.60]	1.15 [0.96, 1.38]	1.14 [0.95, 1.36]	<0.001
LDL cholesterol, mmol/l	3.06 [2.64, 3.64]	3.43 [2.74, 4.00]	2.89 [2.41, 3.52]	<0.001
Triglycerides, mmol/l	1.13 [0.85, 1.40]	1.62 [1.23, 2.12]	1.73 [1.23, 2.33]	<0.001
Alanine-aminotransferase, U/l	23.00 [17.96, 33.00]	27.54 [20.36, 40.06]	31.00 [22.00, 46.86]	<0.001
Aspartate-aminotransferase, U/l	24.00 [21.56, 28.14]	26.35 [22.00, 33.27]	28.00 [22.75, 35.48]	<0.001
γ-Glutamyltransferase, U/l	27.00 [18.56, 37.00]	30.00 [22.00, 46.55]	37.00 [27.54, 58.34]	<0.001
US-CRP, mg/dl	6.52 [3.22, 12.40]	7.45 [4.50, 13.40]	5.30 [2.75, 10.97]	0.004
hs-IL6, pg/ml	3.03 [2.03, 4.23]	3.42 [2.46, 5.03]	3.40 [2.15, 5.04]	0.032
CCCL2, pg/ml	86.55 [66.60, 107.78]	86.61 [66.42, 112.79]	84.56 [61.21, 110.92]	0.524
CXCL5, pg/ml	325.74 [122.81, 12.56 [5.73, 23.19]	252.37 [110.15, 12.12 [5.43, 25.80]	415.39 [131.15, 1087.94]	0.027
Eotaxine, pg/ml	12.56 [5.73, 23.19]	12.12 [5.43, 25.80]	17.35 [10.02, 29.23]	0.001
IL7, pg/ml	4.88 [2.92, 9.17]	4.88 [2.72, 8.05]	4.56 [2.53, 8.19]	0.680
IP10, pg/ml	27.19 [17.22, 42.79]	29.36 [17.11, 50.92]	29.63 [18.29, 48.09]	0.468
MIF, pg/ml	19.78 [5.93, 54.89]	19.50 [5.08, 60.30]	35.02 [7.57, 81.53]	0.003
MIP1b, pg/ml	66.92 [45.94, 90.72]	76.24 [49.84, 123.53]	76.28 [46.97, 112.83]	0.107
SDF1, pg/ml	159.08 [118.93, 743.06 [479.21,	164.86 [118.25, 850.31 [496.89,	156.67 [111.04, 224.24]	0.689
VEGF-A, pg/ml	743.06 [479.21,	850.31 [496.89,	746.95 [469.81, 1169.31]	0.389
sCD14, pg/ml	1341.28 [1154.64,	1389.85 [1171.53,	492.42 [1304.94, 1794.44]	<0.001
Bristol stool score				0.140
Type 1,2	15 (9.3)	10 (4.6)	14 (6.1)	
Type 3,4	120 (74.5)	160 (73.1)	158 (69.3)	
Type 5,6,7	26 (16.1)	49 (22.4)	56 (24.6)	
Antibiotic cures in last 5 y, n				0.966
0	77 (47.8)	102 (46.6)	111 (48.7)	
1	31 (19.3)	40 (18.3)	42 (18.4)	
2	17 (10.6)	31 (14.2)	26 (11.4)	
3+	36 (22.4)	46 (21.0)	49 (21.5)	
Smoking status				0.057
Ancient	54 (34.0)	81 (37.2)	107 (47.8)	
Current	22 (13.8)	39 (17.9)	36 (16.1)	
No	65 (40.9)	76 (34.9)	60 (26.8)	
Passive	18 (11.3)	22 (10.1)	21 (9.4)	
Moderate-to-vigorous intensity leisure-	3.50 [1.12, 7.25]	3.52 [1.22, 9.11]	3.41 [0.58, 8.56]	0.780
Total physical activity excluding work,	80.56 [41.58, 143.33]	65.34 [36.07, 100.78]	63.69 [31.01, 106.48]	0.013
Manual/ heavy manual job (%)	19 (12.1)	33 (15.4)	24 (11.2)	0.402
Total leisure sedentary time, h/week	30.00 [18.00, 43.00]	33.46 [20.00, 47.88]	29.50 [14.00, 47.00]	0.097
Total leisure screen time, h/week	22.00 [14.00, 34.00]	23.00 [16.00, 37.69]	21.00 [11.81, 35.00]	0.084
Biotin intake, µg/day	26.34 [16.91, 40.71]	28.72 [16.62, 43.32]	31.19 [17.04, 57.28]	0.135

Supplementary Table 2

	NOB-MH	NOB-MUH	NOB-T2D	p	MOB-MH	MOB-MUH	MOB-T2D	p
n	284	130	224		13	81	205	
Age, y	57.00 [49.00, 65.00]	65.00 [58.00, 68.75]	63.00 [58.00, 68.00]	<0.001	59.00 [50.00, 66.00]	59.00 [54.00, 66.00]	62.00 [57.00, 67.00]	0.075
Gender = Male	112 (39.4)	72 (55.4)	147 (65.6)	<0.001	6 (46.2)	44 (54.3)	97 (47.3)	0.552
Country				<0.001				<0.001
Denmark	100 (35.2)	88 (67.7)	20 (8.9)		4 (30.8)	40 (49.4)	16 (7.8)	
France	93 (32.7)	28 (21.5)	113 (50.4)		6 (46.2)	38 (46.9)	112 (54.6)	
Germany	91 (32.0)	14 (10.8)	91 (40.6)		3 (23.1)	3 (3.7)	77 (37.6)	
Body mass index, kg/m ²	22.41 [21.21, 23.89]	26.51 [24.81, 28.30]	27.68 [26.56, 28.80]	<0.001	32.84 [31.55, 33.91]	32.31 [31.21, 33.41]	32.21 [31.16, 33.31]	0.600
% Body fat	24.77 [18.77, 30.54]	29.07 [25.74, 38.33]	28.23 [24.94, 37.18]	<0.001	40.65 [34.90, 41.94]	39.06 [31.47, 44.47]	39.53 [31.41, 43.64]	0.912
Waist circumference, cm	79.30 [74.00, 86.00]	96.55 [89.50, 100.70]	99.00 [95.07, 104.03]	<0.001	104.20 [100.20, 109.60]	107.20 [101.50, 113.30]	107.40 [103.00, 113.00]	0.353
Systolic blood pressure, mm hg	121.25 [111.50, 132.62]	135.50 [126.12, 144.88]	134.50 [125.00, 143.50]	<0.001	133.50 [119.50, 145.00]	135.50 [125.00, 146.00]	134.00 [124.00, 145.00]	0.645
Diastolic blood pressure, mm hg	68.00 [63.00, 75.00]	76.50 [69.25, 81.50]	73.50 [66.50, 80.50]	<0.001	76.00 [63.50, 79.00]	76.50 [69.50, 84.00]	75.00 [69.00, 82.00]	0.436
Fasting blood glucose, mmol/l	5.03 [4.70, 5.40]	5.70 [5.40, 6.10]	7.40 [6.10, 8.67]	<0.001	5.40 [4.80, 5.50]	5.80 [5.30, 6.20]	7.40 [6.45, 8.70]	<0.001
HbA1c, %	5.41 [5.25, 5.60]	5.60 [5.40, 5.98]	6.80 [6.30, 7.44]	<0.001	5.40 [5.30, 5.67]	5.70 [5.50, 6.00]	6.92 [6.44, 7.60]	<0.001
HDL cholesterol, mmol/l	1.82 [1.43, 2.12]	1.27 [0.99, 1.54]	1.26 [1.06, 1.57]	<0.001	1.32 [1.11, 1.68]	1.19 [0.94, 1.39]	1.19 [0.98, 1.46]	0.127
LDL cholesterol, mmol/l	3.10 [2.60, 3.70]	3.10 [2.60, 3.70]	2.76 [2.24, 3.39]	<0.001	2.97 [2.58, 3.89]	3.02 [2.50, 3.70]	2.66 [2.11, 3.49]	0.012
Triglycerides, mmol/l	0.81 [0.62, 1.02]	1.31 [0.94, 1.92]	1.37 [0.98, 2.03]	<0.001	1.04 [0.73, 1.30]	1.22 [0.93, 1.82]	1.49 [1.14, 2.03]	<0.001
Alanine-aminotransferase, U/l	20.00 [16.00, 24.28]	29.00 [23.95, 35.75]	27.77 [21.42, 39.00]	<0.001	28.00 [18.00, 36.00]	29.00 [25.50, 37.50]	31.00 [21.00, 45.00]	0.415
Aspartate-aminotransferase, U/l	25.75 [22.00, 30.00]	28.00 [25.00, 32.83]	27.00 [22.16, 34.00]	<0.001	27.54 [20.00, 29.34]	29.00 [24.50, 34.00]	27.00 [22.75, 36.00]	0.258
γ-Glutamyltransferase, U/l	19.00 [14.00, 25.00]	30.00 [20.09, 45.75]	31.57 [22.75, 49.00]	<0.001	22.75 [20.00, 31.00]	35.00 [23.00, 49.00]	38.00 [24.00, 54.00]	0.028
US-CRP, mg/dl	0.83 [0.38, 1.68]	1.21 [0.66, 2.17]	1.60 [0.84, 3.64]	<0.001	1.37 [0.85, 2.70]	1.88 [1.05, 3.66]	2.74 [1.46, 5.79]	0.009
hs-IL6, pg/ml	1.13 [0.78, 1.87]	1.80 [1.28, 2.84]	1.81 [1.30, 2.75]	<0.001	1.86 [1.09, 2.46]	2.37 [1.55, 3.25]	2.37 [1.65, 3.12]	0.395
CCL2, pg/ml	81.62 [65.61, 105.21]	88.93 [69.70, 118.66]	81.60 [63.66, 110.56]	0.161	82.33 [76.52, 102.70]	89.27 [70.24, 108.03]	87.10 [61.46, 111.82]	0.624
CXCL5, pg/ml	369.16 [121.00, 814.68]	505.44 [118.14, 1073.50]	493.68 [141.63, 1241.46]	0.078	381.70 [87.01, 869.27]	296.52 [101.11, 877.71]	597.08 [215.03, 1164.94]	0.011
Eotaxine, pg/ml	22.26 [10.68, 39.41]	25.34 [11.08, 45.68]	23.62 [10.05, 43.31]	0.546	17.85 [6.56, 34.14]	15.89 [7.41, 32.09]	24.91 [10.75, 39.95]	0.045
IL7, pg/ml	4.90 [2.68, 8.50]	5.63 [3.33, 9.70]	5.04 [2.27, 8.98]	0.17	5.33 [2.59, 7.98]	5.82 [3.18, 10.47]	4.40 [2.02, 7.79]	0.100
IP10, pg/ml	21.09 [12.77, 32.12]	28.48 [16.95, 43.92]	21.91 [12.83, 36.34]	<0.001	24.58 [14.65, 41.28]	29.15 [16.09, 42.77]	23.59 [15.81, 36.56]	0.410
MIF, pg/ml	30.27 [8.88, 60.89]	41.09 [7.27, 81.31]	39.66 [8.07, 83.35]	0.063	14.36 [5.28, 57.86]	20.70 [7.78, 68.17]	42.45 [8.64, 75.93]	0.222
MIP1b, pg/ml	60.04 [35.91, 104.12]	85.49 [45.70, 136.18]	67.57 [44.65, 106.71]	0.004	80.82 [59.22, 149.85]	67.44 [46.94, 107.18]	67.07 [40.10, 103.40]	0.211
SDF1, pg/ml	141.69 [105.84, 195.66]	155.28 [117.66, 230.05]	151.59 [110.40, 196.88]	0.105	174.25 [167.31, 262.32]	151.18 [109.22, 207.46]	148.92 [113.42, 202.89]	0.044
VEGF-A, pg/ml	726.28 [412.61, 1199.99]	824.95 [444.87, 1702.61]	707.89 [381.24, 1191.69]	0.071	1027.94 [418.85, 1717.71]	972.90 [472.26, 1403.22]	707.48 [405.85, 1255.46]	0.217
sCD14, pg/ml	1484.06 [1242.28, 1777.89]	1325.38 [1124.28, 1646.40]	1520.13 [1303.39, 1746.86]	<0.001	1346.82 [1005.81, 1495.45]	1378.59 [1107.56, 1641.51]	1443.02 [1198.48, 1670.25]	0.145
Bristol stool score				0.059				0.212
Type 1,2	39 (13.7)	15 (11.5)	18 (8.0)		2 (15.4)	10 (12.3)	19 (9.3)	
Type 3,4	218 (76.8)	98 (75.4)	168 (75.0)		10 (76.9)	65 (80.2)	150 (73.2)	
Type 5,6,7	27 (9.5)	17 (13.1)	38 (17.0)		1 (7.7)	6 (7.4)	36 (17.6)	
Antibiotic cures in last 5 y, n				0.001				0.066
0	168 (59.2)	83 (63.8)	152 (67.9)		10 (76.9)	43 (53.1)	133 (64.9)	
1	62 (21.8)	39 (30.0)	40 (17.9)		3 (23.1)	27 (33.3)	38 (18.5)	
2	34 (12.0)	7 (5.4)	13 (5.8)		0 (0.0)	7 (8.6)	13 (6.3)	
3+	20 (7.0)	1 (0.8)	19 (8.5)		0 (0.0)	4 (4.9)	21 (10.2)	
Smoking status				<0.001				0.603
Ancient	99 (34.9)	63 (48.5)	102 (46.2)		5 (38.5)	37 (45.7)	89 (43.4)	
Current	27 (9.5)	18 (13.8)	28 (12.7)		3 (23.1)	6 (7.4)	21 (10.2)	
No	149 (52.5)	43 (33.1)	73 (33.0)		4 (30.8)	34 (42.0)	77 (37.6)	
Passive	9 (3.2)	6 (4.6)	18 (8.1)		1 (7.7)	4 (4.9)	18 (8.8)	
Moderate-to-vigorous intensity leisure-time	7.69 [4.25, 13.67]	8.50 [4.39, 13.99]	6.55 [1.19, 14.62]	0.057	4.06 [1.25, 10.25]	4.86 [1.82, 8.14]	4.53 [0.62, 11.25]	0.888
Total physical activity excluding work, MET-h/week	87.54 [56.40, 126.33]	91.86 [53.20, 141.52]	82.42 [45.44, 144.60]	0.553	83.54 [39.56, 149.67]	77.72 [42.18, 130.50]	69.15 [38.85, 123.27]	0.640
Manual/ heavy manual job (%)	33 (11.9)	9 (7.0)	24 (11.5)	0.306	2 (15.4)	7 (8.8)	24 (12.2)	0.625
Total leisure sedentary time, h/week	24.00 [14.00, 35.50]	20.50 [11.00, 35.75]	20.00 [11.63, 35.00]	0.078	20.50 [14.00, 40.00]	29.42 [17.12, 42.46]	24.83 [12.00, 39.00]	0.141
Total leisure screen time, h/week	18.00 [9.25, 28.00]	16.00 [8.00, 27.62]	16.00 [8.00, 27.00]	0.192	16.00 [8.50, 32.00]	23.75 [12.75, 35.00]	17.50 [8.00, 31.00]	0.038
Biotin intake, µg/day	32.4 [24.9;43.2]	35.1 [27.2;45.9]	36.2 [23.3;53.6]	0.161	39.7 [23.4;54.4]	29.8 [22.7;36.9]	35.9 [25.8;50.1]	0.011

Supplementary Table S3

	NON-SOB-MH	NON-SOB-MUH	NON-SOB-T2D	SOB-MH	SOB-MUH	SOB-T2D
n	297	211	429	161	219	228
Number of lipid-lowering drugs						
0	286 (96.3)	132 (62.6)	230 (53.6)	161 (100.0)	192 (87.7)	146 (64.0)
1	11 (3.7)	69 (32.7)	183 (42.7)	0 (0.0)	26 (11.9)	74 (32.5)
2	0 (0.0)	10 (4.7)	16 (3.7)	0 (0.0)	1 (0.5)	8 (3.5)
Specific lipid-lowering drugs						
Ezetimibe	0 (0.0)	14 (6.6)	16 (3.7)	0 (0.0)	2 (0.9)	8 (3.5)
Fibrates	0 (0.0)	4 (1.9)	16 (3.7)	0 (0.0)	2 (0.9)	7 (3.1)
Statins	11 (3.7)	71 (33.6)	183 (42.7)	0 (0.0)	24 (11.0)	75 (32.9)
Number of antihypertensive drugs						
0	270 (90.9)	99 (46.9)	139 (32.4)	114 (70.8)	99 (45.2)	68 (29.8)
1	25 (8.4)	48 (22.7)	82 (19.1)	23 (14.3)	48 (21.9)	36 (15.8)
2	2 (0.7)	44 (20.9)	106 (24.7)	18 (11.2)	30 (13.7)	43 (18.9)
3	0 (0.0)	15 (7.1)	63 (14.7)	5 (3.1)	32 (14.6)	39 (17.1)
4	0 (0.0)	2 (0.9)	27 (6.3)	1 (0.6)	6 (2.7)	28 (12.3)
5	0 (0.0)	1 (0.5)	11 (2.6)	0 (0.0)	3 (1.4)	14 (6.1)
6	0 (0.0)	2 (0.9)	1 (0.2)	0 (0.0)	1 (0.5)	0 (0.0)
Specific antihypertensive drugs						
ACE inhibitors	4 (1.3)	28 (13.3)	102 (23.8)	13 (8.1)	43 (19.6)	67 (29.4)
Renin antagonists	297 (100.0)	211 (100.0)	429 (100.0)	161 (100.0)	219 (100.0)	228 (100.0)
Thiazides	3 (1.0)	44 (20.9)	127 (29.6)	18 (11.2)	49 (22.4)	83 (36.4)
Angiotensin II receptor blockers	5 (1.7)	48 (22.7)	144 (33.6)	20 (12.4)	48 (21.9)	71 (31.1)
Beta blockers	14 (4.7)	27 (12.8)	114 (26.6)	10 (6.2)	47 (21.5)	78 (34.2)
Calcium channel blockers	2 (0.7)	42 (19.9)	123 (28.7)	9 (5.6)	35 (16.0)	63 (27.6)
Central blockers	0 (0.0)	2 (0.9)	14 (3.3)	2 (1.2)	6 (2.7)	11 (4.8)
Loop diuretics	0 (0.0)	0 (0.0)	14 (3.3)	4 (2.5)	14 (6.4)	35 (15.4)
K-sparing diuretics	1 (0.3)	15 (7.1)	14 (3.3)	2 (1.2)	7 (3.2)	13 (5.7)
Number of antidiabetic drugs						
0	297 (100.0)	211 (100.0)	40 (9.3)	161 (100.0)	219 (100.0)	57 (25.0)
1	0 (0.0)	0 (0.0)	95 (22.1)	0 (0.0)	0 (0.0)	41 (18.0)
2	0 (0.0)	0 (0.0)	178 (41.5)	0 (0.0)	0 (0.0)	66 (28.9)
3	0 (0.0)	0 (0.0)	70 (16.3)	0 (0.0)	0 (0.0)	27 (11.8)
4	0 (0.0)	0 (0.0)	42 (9.8)	0 (0.0)	0 (0.0)	30 (13.2)
5	0 (0.0)	0 (0.0)	4 (0.9)	0 (0.0)	0 (0.0)	7 (3.1)
Specific antidiabetic drugs						
Metformin	0 (0.0)	0 (0.0)	337 (78.6)	0 (0.0)	0 (0.0)	143 (62.7)
Glitazones	0 (0.0)	0 (0.0)	1 (0.2)	0 (0.0)	0 (0.0)	1 (0.4)
DPP IV inhibitors	0 (0.0)	0 (0.0)	221 (51.5)	0 (0.0)	0 (0.0)	96 (42.1)
Sulfonylurea	0 (0.0)	0 (0.0)	117 (27.3)	0 (0.0)	0 (0.0)	29 (12.7)
SGLT2 inhibitors	0 (0.0)	0 (0.0)	3 (0.7)	0 (0.0)	0 (0.0)	7 (3.1)
GPL-1 receptor agonists	0 (0.0)	0 (0.0)	26 (6.1)	0 (0.0)	0 (0.0)	34 (14.9)
Acarbose	0 (0.0)	0 (0.0)	2 (0.5)	0 (0.0)	0 (0.0)	0 (0.0)
Insulin	0 (0.0)	0 (0.0)	93 (21.7)	0 (0.0)	0 (0.0)	59 (25.9)
Other drugs						
Aspirin	4 (1.3)	28 (13.3)	85 (19.8)	2 (1.2)	9 (4.1)	40 (17.5)
Proton pump inhibitors	8 (2.7)	21 (10.0)	68 (15.9)	17 (10.6)	38 (17.4)	39 (17.1)

Supplementary Table S4

	Overall	NOB-T2D	MOB-T2D	SOB-T2D	p
n	657	224	205	228	
No metformin treatment	177 (26.9)	51 (22.8)	41 (20.0)	85 (37.3)	<0.001
No antidiabetic treatment	97 (14.8)	22 (9.8)	18 (8.8)	57 (25.0)	<0.001
Insulin only	35 (5.3)	13 (5.8)	12 (5.9)	10 (4.4)	0.736
Sulfonylurea only	11 (1.7)	7 (3.1)	3 (1.5)	1 (0.4)	0.070
Other single treatments (excluding Metformin)	17 (2.6)	4 (1.8)	3 (1.5)	10 (4.4)	0.104
Other treatment combinations (excluding Metformin)	17 (2.6)	5 (2.2)	5 (2.4)	7 (3.1)	0.866
Any treatment (combination) including Metformin	480 (73.1)	173 (77.2)	164 (80.0)	143 (62.7)	<0.001
Metformin only	100 (15.2)	37 (16.5)	35 (17.1)	28 (12.3)	0.307
Metformin + DPP IV inhibitors	105 (16.1)	69 (30.8)	52 (25.4)	44 (19.3)	0.019
Metformin + Sulfonylurea	34 (5.2)	16 (7.1)	10 (4.9)	8 (3.5)	0.213
Metformin + Insulin	14 (2.1)	2 (0.9)	6 (2.9)	6 (2.6)	0.285
Metformin + DPP IV inhibitors + Insulin	43 (6.5)	10 (4.5)	14 (6.8)	19 (8.3)	0.246
Metformin + DPP IV inhibitors + Sulfonylurea	45 (6.8)	20 (8.9)	21 (10.2)	4 (1.8)	0.001
Metformin + DPP IV inhibitors + Sulfonylurea + Insulin	19 (2.9)	9 (4.0)	7 (3.4)	3 (1.3)	0.199
Metformin + GLP-1 receptor antagonists + Sulfonylurea	12 (1.8)	3 (1.3)	3 (1.5)	6 (2.6)	0.620
Other combinations of treatments including Metformin	48 (7.3)	7 (3.1)	16 (7.8)	25 (11.0)	0.006